The 6th Annual T-cell Lymphoma Forum took place January 23-25, 2014, in San Francisco, California.

Allo-SCT can be effective in advanced SS, MF

SCT preparation
Credit: Chad McNeeley

A single-center study suggests that transplant can induce remissions and improve survival in certain patients with advanced cutaneous T-cell lymphomas. Allogeneic stem cell transplant (SCT) proved particularly effective in patients with Sézary syndrome (SS). It also conferred benefits to mycosis fungoides (MF) patients with large-cell transformation (LCT), but patients... [Read Article]

Consortium study falls short of expectations

Ranjana Advani, MD

A group’s effort to identify optimal front-line treatment for peripheral T-cell lymphomas (PTCLs) was not as successful as researchers anticipated. The North American PTCL Consortium set out to find a treatment that could best CHOP, as studies have suggested this regimen is inadequate for patients with PTCL. So... [Read Article]

Regimen shows promise for ENKTL

Hui-qiang Huang, MD, PhD

Results of a single-center study suggest that a 3-drug regimen may be a safe and effective treatment option for patients with newly diagnosed or relapsed/refractory extranodal natural killer/T-cell lymphoma (ENKTL). The combination of pegaspargase, gemcitabine, and oxaliplatin (P-Gemox) elicited a high rate of response in this cohort... [Read Article]

TNFRII may play key role in CTCL, speaker says

Dr Alexander Ungewickell

Researchers have found evidence to suggest that tumor necrosis factor receptor II (TNFRII) may be an important driver of cutaneous T-cell lymphomas (CTCLs). The team discovered that a mutation in this receptor—TNFRII T377I—is present in patients with mycosis fungoides (MF) and those with Sézary syndrome (SS). And previous... [Read Article]

Inhibitor appears active in relapsed/refractory TCLs

Attendees peruse posters
at TCLF 2014

Preliminary results of a phase 1 trial suggest the PI3K-delta/gamma inhibitor IPI-145 is active in patients with relapsed or refractory T-cell lymphomas. Among 26 evaluable patients, 9 experienced partial responses to treatment with IPI-145, and 1 achieved a complete response, for an overall response... [Read Article]

A new prognostic model for PTCL?

Adam Petrich, MD

Unlike its predecessors, a new prognostic model suggests race and histology are important predictors of outcome in patients with peripheral T-cell lymphoma (PTCL). Researchers analyzed nearly 9000 patients diagnosed with PTCL in the US and found evidence to suggest that patient age and race, as well as histology... [Read Article]